Immune-related DNA methylation signature associated with APLN expression predicts prognostic of hepatocellular carcinoma

Biocell

article

FEIFEI TIAN¹  HUAN HU¹  DI WANG¹  HUAN DING¹  QINGJIA CHI²  HUAPING LIANG³  WENLI ZENG⁴ 

[1] School of Life Science and Engineering, Southwest Jiaotong University;Department of Engineering Structure and Mechanics, School of Science, Wuhan University of Technology;State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, The Army Medical University;Renmin Hospital of Wuhan University Nursing Department

关键词: TIME;    Immunity;    Prognosis;    Bioinformatics;   

DOI  :  10.32604/biocell.2022.020198

学科分类：仪器

来源: Biocell

【 摘 要 】

This study used transcriptome and epigenetic data to predict the prognosis of immune-related genes (IRGs) Apelin(APLN) in patients with hepatocellular carcinoma (HCC). The TCGA database has gene expression and clinical data for HCC.And DNA methylation 450 k data for HCC was download from the University of California Santa Cruz (UCSC) Xenabrowser. Performing clinical and prognostic analysis of APLN expression, results show that APLN is highly expressed intumor samples. And it has an increasing trend with the development of clinical stage and T stage. To explore theprognostic role of APLN, the Immune-related DNA methylation (DNAm) sites associated with APLN analyzed bybioinformatics. Univariate COX screened the methylation sites that are related to both APLN and survival. The risk scorerelated to methylation site signature was determined according to their least absolute shrinkage and selection operator(LASSO) coefficients. Then the patients were divided into high-risk groups and low-risk groups. Significant differences inoverall survival (OS) were found in the training cohort. Nomogram shows that APLN or methylation signature caneffectively predict the prognosis of HCC patients. In summary, APLN may be a diagnostic and prognostic marker for HCC.

【 授权许可】

CC BY